AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US

TUSTIN, Calif., Sept. 18  /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major assets in China, announced today its stockholders have approved by verbal consent the name change and rebranding of the Company as "Radient Pharmaceuticals Corporation".  The new ticker symbol on the New York Stock Exchange Alternext US will be "RPC".   The Company has filed an amendment to its 'Articles of Incorporation' to implement this change effective prior to the open of the markets on Friday, September 25, 2009.

AMDL believes this name change more accurately reflects the Company's core business and assets given its most recent news announcing the monetization strategy for the Company's China-based subsidiary Jade Pharmaceuticals Inc.; formation of the newly formed, wholly-owned subsidiary AMDL Diagnostics Inc. (ADI) focused on the commercialization of AMDL's proprietary Onko-Sure(TM) In Vitro Diagnostic (IVD) cancer test; and introduction of the new Elleuxe(TM) high-end skin care line.

"Approval of our new name and ticker symbol is a milestone event for our Company," stated Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "We believe Radient Pharmaceuticals as a brand name has considerable bench strength, and clearly represents the Company's core business and market focus, particularly as it relates to the international commercialization of Onko-Sure(TM) and Elleuxe(TM).  It promotes a clear, unified, and consistent brand to the global markets we are targeting with our life-changing products."

In addition to today's rebranding announcement, AMDL completed a note and warrant purchase agreement with St. George Investments, LLC in the amount of approximately $555,555 and a bridge loan with Cantone Asset Management in the amount of $58,000.  For additional information, please refer to the Form 8K filed with the Securities and Exchange Commission (SEC).

Radient Pharmaceuticals Corporations

Radient Pharmaceuticals is actively engaged in the research, development, manufacturing, sales and marketing of in vitro diagnostic (IVD) and high-end skin care products.  The Company has completed a 5-year business strategy outlining its mission, vision, international commercialization plan, and future product development plans for both products.  Simultaneously, Radient Pharmaceutical is aggressively collaborating with its China-based management team to determine the highest valuation path and plan for the de-consolidation of Jade Pharmaceuticals Inc. (JPI).

MacLellan continued, "Along with our corporate name change, we have restructured our business and are re-classifying Jade Pharmaceuticals as a business asset rather than a core operating arm of the Company.  In doing this, we are now able to focus 100% of our work efforts on two critical priorities - successfully developing and delivering life-changing products that make a positive difference in the lives of the people we serve, which in turn will deliver exceptional returns to our valued and loyal shareholders.  At the heart of our business is a straightforward commitment to deliver products that really matter and that commitment is the very essence of who we are."

Products

Onko-Sure(TM): a simple, non-invasive blood test used for the detection and/or monitoring of 14 different types of cancer.

  --  Can be a valuable diagnostic tool in the worldwide battle against
      cancer, the second leading cause of death worldwide.
  --  Serves the IVD cancer/oncology market which is growing at an 11% CAGR
      and is expected to reach $8B by 2012 according to healthcare market
      intelligence group Kalorama.
  --  Sold as a blood test for cancer in Europe (CE Mark certified), India,
      Taiwan, Korea, Vietnam, and in Chile (research use); approved in the
      US for the monitoring of colorectal cancer (CRC); approved in Canada
      (by Health Canada) for lung cancer detection and lung cancer treatment
      monitoring; and in many key markets, has the potential to be used as a
      general cancer screening test.
  --  Radient Pharmaceuticals is selling the Onko-Sure(TM) to healthcare
      distribution partners in key markets around the world.   Distribution
      partners market and sell the kits to hospitals, clinical labs, and
      other healthcare venues (both public and private) that provide testing
      services to patients via appropriate healthcare professionals.  The
      Company also continues to sell kits directly (outside the USA) to
      select research centers for continuing studies and diagnostic research
      use. Cost per test to patients and reimbursement rates vary country to
      country. Radient Pharmaceuticals is also aggressively exploring
      further expansion of test use in private screening clinics in select
      strategic markets.
  --  By 2010 the Company anticipates the launch of a rapid test version of
      Onko-Sure(TM) to further increase market share. The rapid test will
      provide the flexibility and cost effective deployment to significantly
      expand cancer testing and provide diagnostic solutions in emerging
      markets and economies addressing large underserved at-risk
      populations.

  --  By late 2011 the Company anticipates launching a next generation
      version of Onko-Sure(TM) which is expected to deliver increased
      sensitivity and specificity; therefore garnering increased test kit
      price points.  US market launch expected in 2012.




Elleuxe(TM): a therapeutic, high-end skin care product line based on the active ingredient 'Elleuxe Protein' - Radient Pharmaceutical's proprietary active ingredient that offers cell renewing properties designed to minimize the appearance of aging.

  --  The Company anticipates market launch and commercialization of the
      introductory Elleuxe(TM) product line targeted to women in the luxury
      market in late Q1FY10 to early Q2FY10. In FY10, the Company plans to
      launch two additional product lines.  In total there will be eight
      separate product formulations for Elleuxe(TM).
  --  Elleuxe(TM) will be sold directly to high-end retail stores, high-end
      beauty spas and medical day spas.  The Company anticipates it will
      sell the product sets (grouped based on skin types) at between $500
      and $650 and the individual products in the set at $100-$350 per
      ounce.

  --  The Global Luxury Skin Care Market is growing at a 7-8% CAGR and is
      expected to reach $22.1B by FY2013.




For additional information on AMDL and AMDL Diagnostics Inc. please contact AMDL Investor Relations at  or by calling 206.310.5323.

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 510 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law.  These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices.  With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

  AMDL Contact:
  Kristine Szarkowitz
  Director-Investor Relations
  
  (Tel :) 206.310.5323


DATASOURCE: AMDL Inc.



CONTACT:  Kristine Szarkowitz, Director-Investor Relations of AMDL Inc.

[phone], 

Copyright